Gender diverse people's psychological wellbeing and identity in the context of gender affirming speech pathology practice: A qualitative study protocol.

Background: Gender diverse people may experience discomfort with the sound of their voice. Additionally, their psychological wellbeing, closely connected to a person's identity, or perspective of themselves, is often reduced. A primary goal of gender affirming healthcare is to support clients' psychological wellbeing.

Therapeutic relationships in speech-language pathology: A scoping review of empirical studies.

Purpose: This scoping review provides an overview of empirical studies investigating therapeutic relationships between speech-language pathologists (SLPs), clients, and caregivers across all ages and clinical areas, and identifies areas of future research.

Method: The Joanna Briggs Institute's (JBI) scoping review method was employed. Systematic searches were conducted across seven databases and four grey literature databases.

Therapeutic relationships in speech-language pathology: a scoping review protocol.

Objective: The purpose of this scoping review is to provide an overview of empirical research regarding the therapeutic relationship between speech-language pathologists and their clients of all ages and clinical areas.

Introduction: The influence of a positive relationship between professionals and clients on the process and outcome of interventions is well documented for many health professions. However, research in speech-language pathology predominantly focuses on the outcome of specific treatment methods and techniques.

Exploring Adherence to First-Line and Second-Line Immunotherapies in Multiple Sclerosis: An Interview Study.

Background: Treatment adherence is fundamental in multiple sclerosis (MS) management. Adherence rates vary significantly between studies, ranging from 30% to almost 90%, depending on assessment method and medication type. This study aimed to identify patient-related categories associated with treatment modification or discontinuation in people with MS receiving either first- or second-line treatment.